Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Solabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solabegron SCHEMBL2596555 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL2890305 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29386981 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29357347 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29410896 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL565177 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29410905 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL15269302 | 0.98 | ADRB3 (0.96) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6132845 | 0.93 | ADRB3 (0.86) | ADRB3ADRB1ADRB2 | |
| SCHEMBL5703943 | 0.93 | ADRB3 (0.86) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928448-B1 | ASSOCIATION OF ß3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | claimed |
| US-20080182899-A1 | ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | US | claimed |
| US-12435026-B2 | Solabegron zwitterion and uses thereof | B3AR THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240124391-A1 | SOLABEGRON ZWITTERION AND USES THEREOF | B3AR THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-3365321-B1 | SOLABEGRON ZWITTERION AND USES THEREOF | B3AR THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11691944-B2 | Solabegron zwitterion and uses thereof | B3AR THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210317073-A1 | SOLABEGRON ZWITTERION AND USES THEREOF | VELICEPT (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC | 2021-10-14 | — | — | US | disclosed |
| US-10844004-B2 | Solabegron zwitterion and uses thereof | VELICEPT THERAPEUTICS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10751311-B2 | Compositions and methods of using modified release solabegron for lower urinary tract symptoms | VELICEPT THERAPEUTICS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200246292-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | VELICEPT THERAPEUTICS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-10668034-B2 | Pharmaceutical compositions and the treatment of overactive bladder | VELICEPT THERAPEUTCIS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20140286931-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8778998-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | MARCADIA BIOTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2568993-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | Indiana University Research and Technology Corporation (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143208-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20100286275-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20090275626-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1955707-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20080182899-A1 | ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691944-B2 | Solabegron zwitterion and uses thereof | KLK3, BPHL, KLK5 | ADRB3 5/4885ADRB1 17/4885ADRB2 22/4885 |
| US-12435026-B2 | Solabegron zwitterion and uses thereof | KLK3, BPHL, KLK5 | ADRB3 5/4885ADRB1 17/4885ADRB2 22/4885 |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | ADRB3 186/4885ADRB1 147/4885ADRB2 350/4885 |
| US-10844004-B2 | Solabegron zwitterion and uses thereof | KLK3, BPHL, KLK5 | ADRB3 5/4885ADRB1 17/4885ADRB2 22/4885 |
| US-20100286275-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | ADRB3 1/4885ADRB1 2/4885ADRB2 4/4885 |
| US-20210317073-A1 | SOLABEGRON ZWITTERION AND USES THEREOF | KLK3, BPHL, KLK5 | ADRB3 5/4885ADRB1 17/4885ADRB2 22/4885 |
| US-10751311-B2 | Compositions and methods of using modified release solabegron for lower urinary tract symptoms | KLK3, BPHL, ADRB3 | ADRB3 3/4885ADRB1 5/4885ADRB2 6/4885 |
| US-20240124391-A1 | SOLABEGRON ZWITTERION AND USES THEREOF | KLK3, BPHL, KLK5 | ADRB3 5/4885ADRB1 17/4885ADRB2 22/4885 |
| US-20080182899-A1 | ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB1 2/4885ADRB2 3/4885 |
| US-20200246292-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | ADRB3, ADRA2B, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 4/4885 |
| US-10668034-B2 | Pharmaceutical compositions and the treatment of overactive bladder | ADRB3, ADRA2B, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 4/4885 |
| US-20140286931-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | ADRB3 1/4885ADRB1 2/4885ADRB2 4/4885 |
| US-20090275626-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN | ADRB3, ALOX5, LTB4R | ADRB3 1/4885ADRB1 22/4885ADRB2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.